Press Releases on September 17, 2018 - EIN Presswire - Press Release Distribution Service

Published on September 17, 2018 - 12:23 GMT

Human medicines European public assessment report (EPAR): Fotivda, tivozanib hydrochloride monohydrate, Carcinoma, Renal Cell, ...

Fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:23 GMT

Human medicines European public assessment report (EPAR): Fotivda, tivozanib hydrochloride monohydrate, Carcinoma, Renal Cell, ...

Fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:23 GMT

Human medicines European public assessment report (EPAR): Iscover, clopidogrel, Stroke;Peripheral Vascular Diseases;Atrial ...

Iscover was more effective than acetylsalicylic acid at preventing new ischaemic events. In a study in around 19,000 patients who had recently had a heart attack or an ischaemic stroke, or who had established peripheral artery disease, 939 patients who …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:23 GMT

Human medicines European public assessment report (EPAR): Iscover, clopidogrel, Stroke;Peripheral Vascular Diseases;Atrial ...

Iscover was more effective than acetylsalicylic acid at preventing new ischaemic events. In a study in around 19,000 patients who had recently had a heart attack or an ischaemic stroke, or who had established peripheral artery disease, 939 patients who …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:23 GMT

Orphan designation: Cannabidivarin, Treatment of fragile X syndrome, 22/02/2018, Positive

Fragile X syndrome is an inherited disease characterised by learning disability. Other symptoms include difficulty communicating and socialising, anxiety, hyperactivity (restlessness), and repetitive and stereotyped behaviours. The disease is caused by a …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:23 GMT

Human medicines European public assessment report (EPAR): Docetaxel Accord, docetaxel, Head and Neck Neoplasms;Carcinoma, Non-...

Breast cancer Docetaxel Accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with: operable node-positive breast cancer; operable node-negative breast cancer. For patients with operable node- …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:23 GMT

Human medicines European public assessment report (EPAR): Docetaxel Accord, docetaxel, Head and Neck Neoplasms;Carcinoma, Non-...

Breast cancer Docetaxel Accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with: operable node-positive breast cancer; operable node-negative breast cancer. For patients with operable node- …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:23 GMT

Human medicines European public assessment report (EPAR): Busilvex, busulfan, Hematopoietic Stem Cell Transplantation, Date of ...

Busilvex followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in adult patients when the combination is considered the best available option. Busilvex …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:23 GMT

Human medicines European public assessment report (EPAR): Busilvex, busulfan, Hematopoietic Stem Cell Transplantation, Date of ...

Busilvex followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in adult patients when the combination is considered the best available option. Busilvex …

Distribution channels: Healthcare & Pharmaceuticals Industry